Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795830 | 0.93 | CCR1 (0.42) | CCR1PDE4BPDE11AMLYCDPDE10A | |
| SCHEMBL19682 | 0.93 | CCR1 (0.42) | CCR1PDE4BPDE11AMLYCDPDE10A | |
| SCHEMBL20971 | 0.91 | KCNQ3 (0.44) | CCR1PDE4BPDE11AMLYCDPDE10A | |
| SCHEMBL20185 | 0.90 | KCNQ3 (0.53) | KCNQ3KCNQ2TP53TACR1RECQL | |
| SCHEMBL1722162 | 0.87 | DDR1 (0.42) | CCR1PDE4BPDE11AMLYCDPDE10A | |
| SCHEMBL20573 | 0.85 | KCNQ3 (0.45) | PDE10AKCNQ3KCNQ2MAPK1TP53 | |
| SCHEMBL30796198 | 0.85 | KCNQ3 (0.45) | PDE10AKCNQ3KCNQ2MAPK1TP53 | |
| SCHEMBL21552 | 0.83 | KCNQ3 (0.46) | PDE10AKCNQ3KCNQ2MAPK1RECQL | |
| SCHEMBL21147 | 0.83 | MLYCD (0.42) | CCR1PDE4BPDE11AMLYCDPDE10A | |
| SCHEMBL30795067 | 0.83 | KCNQ3 (0.46) | PDE10AKCNQ3KCNQ2MAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | claimed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | claimed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | claimed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-9073862-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CCR1 4505/4885PDE4B 1701/4885PDE11A 3560/4885 |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CCR1 4505/4885PDE4B 1701/4885PDE11A 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.